【摘要】 目的:对乳腺癌组织中,核苷酸切除修复交叉互补基因1(Excision repair cross comp-lementing,ERCC1)、Ki67蛋白、增殖细胞核抗原(Proliferating cell nuclear antigen,PCNA)表达与蒽环类化疗药物敏感性的关系进行探讨。方法:通过免疫组化法对93例乳腺癌组织的ERCC1、Ki67和PCNA表达进行检测;观察患者化疗疗效,对ERCC1、Ki67和PCNA表达水平不同患者使用蒽环类药物化疗的效果差异进行比较。结果:ERCC1的阳性率为65.59%,Ki67的阳性率为69.89%,PCNA的阳性率为64.52%。ERCC1阳性组总有效率为50.82%,ERCC1阴性组总有效率为84.38%;Ki67阳性组中,Ki67表达强度为25%~50%患者有效率为73.68%(14/19),50%~75%患者有效率为85.71%(24/28),>75%患者有效率为88.89%(16/18),Ki67阴性组总有效率为60.71%;PCNA阳性组中,PCNA表达强度为25%-50%患者有效率为52.94%(9/17),50%~75%患者有效率为62.07%(18/29),>75%患者有效率为71.43%(10/14),PCNA阴性组总有效率为81.82%,以上差异均有统计学意义(P<0.01,P<0.05,P<0.05)。结论:乳腺癌患者ERCC1、Ki67和PCNA的表达情况与蒽环类化疗药物的敏感性均有相关关系,而在临床上对多因子的联合检测将更有助于化疗药物的选择以及化疗方案的制定。更多还原

【Abstract】 Objective: To explore the relationship between ERCC1,Ki67,PCNA expression with anthracycline chemotherapeutic drugs’ sensitivities in breast cancer tissues. Methods: The ERCC1,Ki67,PCNA expression in 93 breast cancer tissue was detected by immunohistochemical staining. The efficacy of chemotherapy was observed and the difference of anthracycline chemotherapy effect among patients with different ERCC1,Ki67,PCNA expression was compared. Results: The positive rate of ERCC1 was 65. 59%,the positive rate of Ki67 was 69. 89%,the positive rate of PCNA was 64. 52%. The total effective rate of ERCC1-positive group was 50. 82%,and ERCC1-negative group was 84. 38%. In Ki67-positive group,the effective rate of patients in 25%- 50% intensity was 73. 68%,the effective rate of patients in 50%- 75% intensity was 85. 71%,the effective rate of patients in > 75% intensity was 88. 89%,and Ki67-negative group was 60. 71%. In PCNA-positive group,the effective rate of patients in 25%- 50% intensity was 52. 94%,the effective rate of patients in 50%- 75% intensity was 62. 07%,the effective rate of patients in > 75% intensity was 71. 43%,and PCNA-negative group was 81. 82%. These differences were all statistically significant( P < 0. 01,P < 0. 05,P < 0. 05). Conclusion:There are correlations between ERCC1,Ki67,PCNA expression with anthracycline chemotherapeutic drugs’ sensitivity of patients with breast cancer. Combined detection of multi-factor in clinical is more helpful for the selection of chemotherapy drugs and the formulation of chemotherapy regimen.更多还原